Stock CU6 CLARITY PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Clarity Pharmaceuticals Ltd

Equities

CU6

AU0000165375

Market Closed - Australian S.E.
Other stock markets
 07:10:16 22/05/2024 BST 		5-day change 1st Jan Change
4.07 AUD -0.49% Intraday chart for Clarity Pharmaceuticals Ltd +5.99% +114.21%
04-24 Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer MT
04-04 Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer
MT
Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes
MT
Clarity Pharmaceuticals Concludes Placement and Institutional Entitlement Offer; Shares Decline 4%
MT
Clarity Pharmaceuticals to Raise AU$121 Million via Fully Underwritten Equity Raising
MT
Clarity Pharmaceuticals' SECuRE Trial Treats First Participant in Last Dose Escalation Cohort; Shares Down 5%
MT
Clarity Pharmaceuticals Ltd(ASX:CU6) added to S&P/ASX All Ordinaries Index
CI
Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial
CI
Clarity Pharmaceuticals Prostate Cancer Trial Advances
MT
Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range
CI
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Clarity Pharmaceuticals Reports Safety, Effectivity of Prostate Cancer Lesion Detection System in US Trial
MT
Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors
CI
Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA
CI
Clarity Pharmaceuticals Doses First Patient in Phase Three Prostate Cancer Trial
MT
Clarity Pharmaceuticals Closes Recruitment for Phase 2 Trial in Neuroendocrine Tumors
MT
Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer
CI
Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level
CI
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
AQ
Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE
CI
Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CU6 Stock
  4. News Clarity Pharmaceuticals Ltd